FDA Import Alerts and How Customs Detains Research Chemicals

A shipment of research-grade peptide — labeled for research use only, like everything in this catalog — can sit at a port for three weeks without anyone ever cutting the tape on the container. No sample drawn. No test run. No finding of any kind about what is inside. The hold was decided before the freight left the origin port, against a pattern, by a screening system reading a document the FDA published months earlier. That document is an import alert.

That research-use designation is part of this story rather than an exemption from it. If you're researching a compound and wondering why lead times moved, why a certificate of analysis arrived from a different manufacturing site than last quarter, or why a supplier changed sourcing without changing the molecule, an FDA import alert is often the answer. Below: what an alert is, how detention without physical examination works, which alerts reach peptides, and what the clock looks like once a shipment is held.

What an FDA import alert actually is

Short answer: a standing instruction to agency field staff, not a court ruling about a product.

The agency describes import alerts as documents that notify the public, the import community, and FDA staff of the products and firms that appear to be in violation of FDA laws and regulations. Authority traces to Section 801 of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 381. Alerts get published, numbered, and revised over time. Functionally, one reads less like a verdict than like a filter configuration — a description of what to catch at the border, and what to do with it once caught.

What gives an alert teeth is detention without physical examination, abbreviated everywhere as DWPE. Under an active alert, the agency can detain a shipment and refuse its entry on alert status alone. Nothing is tested. Nothing is examined. The container is the last thing anyone would look at, if anyone looks at all.

Here's the part that catches people off guard. The pattern an alert describes doesn't have to be about the goods at all — it can attach to the manufacturer, the shipper, the importer, or the country of origin. A chemically sound article with a clean analytical record can be held over who packed it or where it transited.

The appearance standard, and who carries the burden

Short answer: the agency doesn't need to prove a violation — and the importer, not the agency, has to show otherwise.

Import alerts run on what the agency calls an appearance standard. It may refuse an article that appears to violate the statute, without definitive proof that it does. That bar sits low by design, for a structural reason: the volume of entry lines crossing a U.S. port far exceeds the laboratory capacity available to test them. A system demanding analytical confirmation before any hold would hold nothing.

The flip side is explicit. A product subject to DWPE will be detained and refused unless the importer can overcome the appearance of the violation(s) by demonstrating to the FDA that the product does not have the violation(s) listed on the import alert. The burden shifts at the moment of detention, onto whoever is trying to bring the goods in. For anyone sourcing research-grade material, that one sentence is the practical core of the whole subject: documentation quality is what moves an entry, and it has to exist before the shipment is already sitting on a dock.

Red List, Yellow List, Green List

Short answer: which list a manufacturer lands on decides what happens to its freight.

Red and Yellow Lists name the firms and products subject to DWPE under a given alert. A Green List does the opposite, naming firms and products exempted from it. The structural detail that matters: absence from the Green List is itself enough to keep a shipment detainable.

Against a single named bad actor, that's unremarkable. Written against an entire product category, it inverts the default — every shipment in the category becomes detainable unless its manufacturer has affirmatively earned a place on the exemption list. The question stops being whether a shipment looks problematic and becomes whether the firm behind it is already on the right list. That alone explains most of why a careful supplier's material still gets held.

Which import alerts actually reach peptides and research chemicals

Short answer: at least three, and the most consequential one covers an entire peptide class.

Import Alert 66-80 — GLP-1 receptor agonist bulk drug substances

The alert titled Detention Without Physical Examination of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Bulk Drug Substances is the clearest example of a class-wide instrument. The agency reported that 21% of 48 evaluated GLP-1 active pharmaceutical ingredient manufacturing sites showed noncompliance with current good manufacturing practice requirements. It also described a recurring sequence: firms registering as GLP-1 manufacturers, offering material for entry, declining requests for records, then deregistering — all inside short windows.

Three charges are cited. Section 501(a)(2)(B), where manufacturing methods do not conform to CGMP. Section 501(j), which finds adulteration where a firm delays or denies an inspection or fails to produce records. And Section 801(a)(3), the refusal-of-admission provision. Worth being precise here, because adulterated does a lot of work in regulatory text: these are manufacturing-controls findings about a facility's records and process validation, not laboratory findings that any container held contaminated material. If that distinction is new, start with our primer on the difference between misbranded and adulterated under the FDCA.

Import Alert 66-40 — firms that have not met drug CGMPs

The companion instrument, Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs, reaches a foreign establishment that has failed an inspection or regulatory assessment. Its drug articles can be detained without physical examination until the firm documents corrective action. Scope runs on the Section 201(g)(1) drug definition, which reaches articles intended to affect the structure or any function of the body — broad enough that classification turns on intended use rather than chemical identity.

A note on nomenclature that matters at the border: research-grade material carrying a name that is also an INN or USAN drug name — Semaglutide, Tirzepatide, Retatrutide, BPC-157 — is not equivalent to the FDA-approved pharmaceutical product of the same name. They're different articles with different entry pathways, and sharing a name doesn't merge them.

Why intended use, not the molecule, decides how an entry is classified

Short answer: what a seller claims can reclassify an article even when the chemistry never changes.

The third relevant instrument is Import Alert 66-41, Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S. Articles promoted with medicinal claims are handled as new drugs within the meaning of Section 201(p) without an approved application, barred from interstate commerce by Section 505(a), and refused under Section 801(a)(3). Coverage spans skin preparations, herbal articles, and anything else carrying therapeutic claims in its labeling. The trigger is the claim set, not the compound. Which is why two containers of identical powder can face completely different entry outcomes.

For research-use material, the honest version is this: a research-use designation is a statement about intended use, and it holds only if everything else a seller says is consistent with it. Promotional language on a product page, in an email, or in a social post can re-characterize the same molecule. Our explainers on the intended-use doctrine and what research-use-only labeling actually requires go through the mechanics.

How a shipment gets flagged in the first place

Short answer: electronically, before a human being ever reads the entry line.

Entry data transmitted at the border is screened by agency systems first. Entries with complete, accurate, and valid data may receive a lower risk score and may be eligible for a release without further review. Data quality at submission — not only the nature of the goods — shapes whether freight moves.

From there a reviewer has three options. Release, meaning the article can be distributed into U.S. commerce, though release doesn't preclude future action if a problem surfaces later. Request additional information, either through entry documents (a Documents Required status) or through examination and sample collection. Or request a detention — issued where a violation is apparent, or where the reviewer cannot verify compliance from the available record. That second pathway deserves emphasis: a documentation gap is sufficient grounds on its own.

Two mechanisms sit on the submission side. Affirmation of Compliance codes are three-letter declarations transmitted with the entry; supplying the correct codes makes it less likely a shipment is held for further entry review. And for articles entering for research, investigations, studies, or training that do not conform to otherwise applicable standards, the path differs — Form FDA 766 may be required, carrying a description of the article, the purpose of the importation, how it will be used, where it will be located, and how long it will remain in the country. Stated plainly: the research-entry pathway is a documented declaration with an evidentiary burden attached, not a label phrase that exempts an article from review.

The detention timeline: notice, hearing period, reconditioning, refusal

Short answer: a clock starts, and missing it ends the matter.

The agency issues a Notice of FDA Action in the form of a Notice of Detention and Hearing, carrying a respond-by date. Oral or written testimony may be submitted to overcome the appearance of a violation, and the Import Trade Auxiliary Communication System (ITACS) is the preferred channel, with local import offices also accepting email, mail, and fax.

The timing has two numbers, which is a common source of confusion. Regulatory Procedures Manual Chapter 9 allows 10 business days from the date of detention. The notice itself generally states 20 calendar days, absorbing weekends, holidays, and mailing time. The date printed on the notice governs, and extensions are available where requested inside that window with reasonable justification.

Standing to respond belongs to the owner, consignee, or importer of record — or to a designated representative holding written authorization. Where a defect is correctable, Form FDA 766 requests permission to relabel or recondition the article instead of losing it outright. If nothing arrives by the respond-by date, the compliance officer can issue a refusal of admission.

After a refusal: 90 days, the customs bond, and a public record

Short answer: a refusal costs more than the shipment.

A refusal is FDA's final decision that a detained shipment is in violation of FDA laws and regulations. The importer then has 90 days from the notice to export or destroy the shipment under the supervision of Customs and Border Protection and the agency. Fail to present the article inside that window and CBP will demand redelivery to an approved port, with authority to assess liquidated damages against the bond — a cost that attaches to the customs bond rather than to the goods.

Then there is the tail. Refusals are published monthly in the public Import Refusals Report, organized by country and product category, which turns a single refused entry into a durable public fact rather than a private loss. Enforcement signals compound across instruments, and reading them together is its own skill — see our walkthrough of FDA warning letters sent to research peptide sellers. Getting off a Red List requires documenting that the condition giving rise to the appearance of a violation was resolved, submitted to the agency's import alert mailbox and, in CGMP cases, typically confirmed by a follow-up inspection.

Frequently Asked Questions

Does an import alert mean a chemical is illegal?

No. An import alert is an entry-screening instruction, not a finding that an article is contraband. It tells field staff that shipments matching a described pattern appear to violate the statute and may be detained without physical examination. The word appear is doing real work: the agency is acting on a risk pattern it already documented, and the importer may rebut it on the individual entry.

Why would a shipment be detained when nothing was found wrong with it?

Because detention without physical examination doesn't require anything to be found. Under an active alert, the alert status itself is the basis for the hold — no sample is drawn and no test is run first. Entry review can also request a detention where a reviewer cannot verify compliance from the submitted record, so a documentation gap is sufficient grounds on its own.

What is a Green List, and why does it matter so much?

A Green List is the exemption roster attached to a specific import alert. Firms and products named on it are not subject to detention without physical examination under that alert; everything not named on it is. On a class-wide alert such as Import Alert 66-80 for GLP-1 bulk drug substances, that inverts the usual default — the question becomes whether the manufacturer has already earned a place on the exemption list.

How long does an importer have to respond to a detention?

The Regulatory Procedures Manual sets the period at 10 business days from the date of detention, but the Notice of FDA Action generally states 20 calendar days to absorb weekends, holidays, and mailing time. The date printed on the notice governs. Extensions are available on timely request with reasonable justification; if nothing arrives by the deadline, the compliance officer can issue a refusal of admission.

What This Means If You're Sourcing Research Material

Import screening is a documentation contest decided against a pattern — not a verdict on a molecule. The appearance standard, the Green List structure, and the burden-shifting at detention all point the same direction: the record assembled before a shipment moves determines whether it moves at all. For a researcher, that reframes supply questions usefully — asking which manufacturing site a batch came from, and what its regulatory standing looks like, tells you more than asking what the compound is.

One caveat: alert text and Green Lists are revised continuously. For any specific article, the authoritative answer is the current alert on the agency's import alert index, read alongside Regulatory Procedures Manual Chapter 9.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.